Tirzepatide
Dual GIP / GLP-1 receptor agonist studied for glycemic control and metabolic pathway research.
Testing & quality
Every batch is supplier-tested for identity and purity and randomly verified by independent third-party HPLC and mass spectrometry.
Compound classification
Synthetic 39-amino-acid dual GIP/GLP-1 receptor agonist.
Mechanism studied in the literature
Activates both the GIP and GLP-1 receptors. Investigated in vitro and in preclinical models for synergistic effects on insulin secretion, glucagon suppression, and adipocyte signaling.
Research areas
- Incretin receptor signaling cascades
- Preclinical models of metabolic dysregulation
- Comparative agonist pharmacology
- Body composition and adipose tissue studies
Storage
Lyophilized: -20°C, protected from light. Reconstituted: 2-8°C, use within 28 days under sterile conditions.
Reconstitution (laboratory)
Reconstitute with bacteriostatic water or sterile water for injection (USP grade). Swirl gently to dissolve.
Related research peptides
Retatrutide
Triple agonist (GLP-1 / GIP / glucagon) studied for body composition and metabolic regulation research.
MOTS-c
Mitochondrial-derived peptide studied for insulin sensitivity, energy expenditure, and metabolic homeostasis.
SLU-PP-322
ERR agonist researched for exercise mimetic effects and mitochondrial biogenesis.
AOD-9604
HGH fragment 176-191 studied for lipolytic and metabolic pathway research.